^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Panvac-VF (falimarev/inalimarev)

i
Other names: CV-301, CVAC-301, CEA-MUC-1-TRICOM, vaccinia-carcinoembryonic antigen (CEA)- mucin-1 (MUC-1)- triad of costimulatory molecules (TRICOM) vaccine, CV301, CEA-MUC-1/TRICOM, MVA-BNCV301/FPVCV301
Associations
Company:
Bavarian Nordic, National Cancer Institute - Bethesda
Drug class:
MUC1 inhibitor, CEA inhibitor
Associations
2ms
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov)
P2, N=32, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2024
Trial completion • Trial completion date • Metastases
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
5ms
Trial completion • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)
7ms
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov)
P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2024 --> Apr 2025
Trial completion date • Surgery
|
Leukine (sargramostim) • Panvac-VF (falimarev/inalimarev)
7ms
HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov)
P2, N=78, Active, not recruiting, Patrick Boland | Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Mar 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Panvac-VF (falimarev/inalimarev)
9ms
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
P2, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
Trial completion date • Trial primary completion date
|
bintrafusp alfa (M7824) • Panvac-VF (falimarev/inalimarev) • ProstVac (rilimogene galvacirepvec)
1year
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov)
P2, N=32, Active, not recruiting, National Cancer Institute (NCI) | Completed --> Active, not recruiting | N=23 --> 32 | Trial completion date: Feb 2023 --> Jan 2026
Enrollment closed • Enrollment change • Trial completion date • Metastases
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
1year
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma (clinicaltrials.gov)
P1/2, N=8, Terminated, Georgetown University | Active, not recruiting --> Terminated; Study closed due to lack of enrollment.
Trial termination • Combination therapy • Metastases
|
Avastin (bevacizumab) • Imfinzi (durvalumab) • capecitabine • Panvac-VF (falimarev/inalimarev)
over1year
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
P2, N=29, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed
|
bintrafusp alfa (M7824) • Panvac-VF (falimarev/inalimarev) • ProstVac (rilimogene galvacirepvec)
over1year
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 amplification • HER-2 negative • CDKN2A negative
|
bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)
over1year
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov)
P2, N=23, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Feb 2023 | Trial primary completion date: Jul 2024 --> Oct 2022
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
MUC1 (Mucin 1) • CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
almost2years
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov)
P2, N=23, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=80 --> 23
Enrollment closed • Enrollment change • Metastases
|
MUC1 (Mucin 1) • CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
2years
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma. (PubMed, Cancer Immunol Immunother)
A Phase 2, single-arm trial was designed to evaluate CV301 plus atezolizumab as first-line treatment for cisplatin-ineligible advanced urothelial carcinoma (aUC) (Cohort 1) or progressing after platinum chemotherapy (Cohort 2). Patients exhibiting benefit demonstrated T-cell response to CEA and MUC-1. The trial illustrates the challenges in the development of vaccines, which should be guided by robust preclinical data.
P2 data • Journal
|
MUC1 (Mucin 1) • ICAM1 (Intercellular adhesion molecule 1) • CD58 (CD58 Molecule)
|
cisplatin • Tecentriq (atezolizumab) • Panvac-VF (falimarev/inalimarev)
over2years
Combination therapy • Trial primary completion date
|
FoundationOne® CDx
|
Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Panvac-VF (falimarev/inalimarev)
over2years
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) (clinicaltrials.gov)
P1/2, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> May 2024 | Trial primary completion date: Dec 2025 --> Oct 2021
Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • HER-2 amplification • HER-2 negative • CDKN2A negative
|
bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)
over2years
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov)
P2, N=80, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jul 2023 --> Jul 2024
Trial primary completion date
|
MUC1 (Mucin 1) • CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
over2years
Clinical
|
MUC1 (Mucin 1) • CXCR1 (Chemokine (C-X-C motif) receptor 1)
|
bintrafusp alfa (M7824) • Panvac-VF (falimarev/inalimarev)
almost3years
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov)
P2; N=78; Active, not recruiting; Sponsor: Kristen Spencer; Trial primary completion date: Dec 2021 --> Jun 2022
Combination therapy • Trial primary completion date
|
FoundationOne® CDx
|
Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Panvac-VF (falimarev/inalimarev)
almost3years
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov)
P2, N=80, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting | N=14 --> 80
Enrollment open • Enrollment change
|
MUC1 (Mucin 1) • CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
3years
Clinical • Enrollment closed • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • HER-2 amplification • HER-2 negative • CDKN2A negative
|
bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)
3years
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov)
P2, N=14, Suspended, National Cancer Institute (NCI) | N=80 --> 14 | Recruiting --> Suspended
Clinical • Enrollment change • Trial suspension
|
MUC1 (Mucin 1) • CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
3years
Clinical • Enrollment change • Trial suspension • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • HER-2 amplification • HER-2 negative • CDKN2A negative
|
bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)
over3years
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov)
P2; Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2020 --> Dec 2021
Combination therapy • Trial primary completion date • Enrollment closed
|
FoundationOne® CDx
|
Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Panvac-VF (falimarev/inalimarev)
almost4years
Clinical • Enrollment open • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • HER-2 amplification • HER-2 negative • CDKN2A negative
|
bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)
4years
Clinical • New P1/2 trial • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • HER-2 amplification • HER-2 negative • CDKN2A negative
|
bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)
4years
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov)
P2, N=80, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
MUC1 (Mucin 1) • CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
over4years
Clinical • New P2 trial
|
MUC1 (Mucin 1) • CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
over4years
Clinical • Trial completion • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CEACAM5 (CEA Cell Adhesion Molecule 5)
|
PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK translocation • CEACAM5 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Panvac-VF (falimarev/inalimarev)